EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

Joaquina C Baranda, Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro, Minal Barve, Jean-Jacques Grob, Oliver Bechter iD, Maria Vieito, Maria Jose de Miguel, Dirk Schadendorf, Melissa Johnson und 9 weitere

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13854 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Joaquina C Baranda und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Kansas Cancer Center, Fairway, Kansas, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Maximum Tolerated Dose. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SAR439459 (SAR'459), a “second‐generation” human anti‐transforming growth factor beta (TGFβ) monoclonal antibody, enhances the activity of immune checkpoint inhibitors. In this phase I/Ib study, we evaluated the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of SAR'459 ± cemiplimab (intravenous) in patients with advanced solid tumors. Increasing doses of SAR'459 were administered every 2 or 3 weeks (Q2W, Q3W) alone (Part 1A) or with 3 mg/kg cemiplimab Q2W or 350 mg Q3W (Part 1B). In Part 2A (dose expansion), melanoma patients were randomly (1:1) administered 22.5 or 7.5 mg/kg SAR'459. In Part 2B (dose expansion), 22.5 mg/kg SAR'459 and 350 mg cemiplimab Q3W were administered. The primary end points were maximum tolerated dose (MTD) or maximum administered dose (MAD; Part 1), preliminary antitumor activity (Part 2B), and optimal monotherapy dose (Part 2A). Twenty‐eight and 24 patients were treated in Parts 1A and 1B, respectively; MTD was not reached, MAD was 15 (Q2W) and 22.5 mg/kg (Q3W) alone and in combination, respectively. Fourteen and 95 patients, including 14 hepatocellular carcinoma (HCC) patients, were treated in Parts 2A and 2B, respectively. The population PK model yielded satisfactory goodness‐of‐fit plots and adequately described the observed data by a two‐compartment PK model with linear elimination. Objective responses were not observed in Parts 1 and 2A. In Part 2B, objective response rate was 8.4% and 7.1% across tumor types and the HCC cohort, respectively. The most frequent treatment‐emergent adverse effects were hemorrhagic events (43.5%), keratoacanthoma (6.8%), and skin neoplasms (6.2%). Fatal bleeding occurred in 21.4% HCC patients despite the implementation of mitigation measures. SAR'459 monotherapy and combination with cemiplimab appeared relatively safe and tolerable in limited number of patients in dose escalation. However, the study was discontinued due to the unclear efficacy of SAR'459 and bleeding risk, particularly in HCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMaximum Tolerated DoseHumansMaleFemaleMiddle AgedAgedAdultDose-Response Relationship, DrugTransforming Growth Factor betaDrug Administration ScheduleAged, 80 and overTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedcemiplimabTransforming Growth Factor betadostarlimab

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Kansas Cancer Center, Fairway, Kansas, USA.
  • Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USA.
  • START Madrid Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Department of Biomedical Sciences, Humanitas University Via Rita Levi Montalcini, Pieve Emanuele, Milan, Italy.
  • IRCCS Humanitas Research Hospital-Humanitas Cancer Center Via Manzoni, Rozzano, Milan, Italy.

ORCID-Profile: Oliver Bechter, Cathy Cantalloube

Zitieren

APA

Baranda, J. C., Robbrecht, D., Sullivan, R., Doger, B., Santoro, A., Barve, M., Grob, J. J., Bechter, O., Vieito, M., de Miguel, M. J., Schadendorf, D., Johnson, M., Pouzin, C., Cantalloube, C., Wang, R., Lee, J., Chen, X., Demers, B., Amrate, A., …, & Hodi, F. S. (2024). Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study. Clinical and Translational Science. https://doi.org/10.1111/cts.13854

Vancouver

Baranda JC, Robbrecht D, Sullivan R, Doger B, Santoro A, Barve M, et al. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study. Clinical and Translational Science. 2024. doi:10.1111/cts.13854

BibTeX
@article{Baranda2024,
  author = {Baranda, Joaquina C and Robbrecht, Debbie and Sullivan, Ryan and Doger, Bernard and Santoro, Armando and Barve, Minal and Grob, Jean-Jacques and Bechter, Oliver and Vieito, Maria and de Miguel, Maria Jose and Schadendorf, Dirk and Johnson, Melissa and Pouzin, Clemence and Cantalloube, Cathy and Wang, Rui and Lee, Jooyun and Chen, Xiaofei and Demers, Brigitte and Amrate, Amele and Abbadessa, Giovanni and Hodi, F Stephen},
  title = {Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13854}
}
Kostenlos starten →